REGENERON PHARMACEUTICALS INC (REGN) - Price, trends, fundamentals and chart - Passport to Wall Street

REGENERON PHARMACEUTICALS INC (NASDAQ: REGN)

Overview

current price

$797.00

$797.00

change

0.00 | 0.00%

0.00 | 0.00%

Yesterday's Close

797.00

open

0.00

volume

0.00 M

30d. avg volume.

0.82 M

1 day

0.00 - 0.00

52 weeks

541.00 - 821.11

p/e

19.72

beta

0.2152

market cap

80.61 B

dividend yield

0.47%

Industry

-

News and Commentary

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Fo... The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficien...

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US AstraZeneca plc (AZN&nb...

Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? Despite a powerful 22% surge in the S&P 500 since the April lows-driven by easing U.S.-China trade tensions and a 90-day pause on new tariffs-only half of the index's stocks have...

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline U.S. President Donald Trump, on Tuesday, disclosed plans for a "major tariff" on foreign pharmaceuticals."We're going to be announcing very shortly a ma...

Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst Wednesday, Johnson & Johnson (...

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stol... U.S. drug wholesaler Cencora Inc (

AI Integration In Biotech & Pharma: Companies Positioned To Benefit The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug dis...

$1 Billion Deal For Moderna To Expand Product Pipeline In China The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in...

FDA Pulls Authorization for GSK Antibody Drug Ineffective Against New Omicron Strain The U.S. Food and Drug Administration (FDA) has withdrawn its authorization for GlaxoSmithKline plc's

FDA Withdraws Authorization for Regeneron and Eli Lilly Antibody Treatments For Use The U.S. Food and Drug Administration (FDA) has withdrawn its authorization for monoclonal antibody treatments manufactured by Regeneron

StockTwits

StockTwits

Join now and unlock premium features

Access to premium stock and ETF data including financials, holdings and more
Participate in trading contests and earn real prizes
Sync you favorite articles and symbols between all of your device
And much more